Abstract
Ebola virus disease is a severe disease, often fatal, with a mortality rate of up to 90%. Presently, effective treatment and safe prevention options for Ebola virus disease are not available. Therefore, there is an urgent need to develop control measures to prevent or limit future Ebola virus outbreaks. Ebola virus protein-based virus-like particle (VLP) and inactivated whole virion vaccines have demonstrated efficacy in animal models, and the addition of appropriate adjuvants may provide additional benefits to these vaccines, including enhanced immune responses. In this study, we screened 24 compounds from injectable excipients approved for human use in Japan and identified six compounds that significantly enhanced the humoral response to Ebola VLP vaccine in a murine model. Our novel adjuvant candidates for Ebola VLP vaccine have already been demonstrated to be safe when administered intramuscularly or subcutaneously, and therefore, they are closer to clinical trials than adjuvants whose safety profiles are unknown.
Highlights
IntroductionEbola virus disease (EVD), discovered in 1976 in South Sudan and Zaire ( known as the Democratic Republic of the Congo, DRC), is an acute disease with a fatality rate that varies from25%–90% [1]
Ebola virus disease (EVD), discovered in 1976 in South Sudan and Zaire, is an acute disease with a fatality rate that varies from25%–90% [1]
The High Five Cells, which were co-infected with recombinant baculoviruses (rBV)-GP and rBV-VP40 viruses, produced filamentous particles from the cell as observed by Transmission Electron Microscopy (TEM)
Summary
Ebola virus disease (EVD), discovered in 1976 in South Sudan and Zaire ( known as the Democratic Republic of the Congo, DRC), is an acute disease with a fatality rate that varies from25%–90% [1]. Ebola virus disease (EVD), discovered in 1976 in South Sudan and Zaire ( known as the Democratic Republic of the Congo, DRC), is an acute disease with a fatality rate that varies from. An Ebola outbreak has been occurring in the DRC since August 2018, with 3409 cases and 2236 death as of 22 January 2020 [3]. Ebolavirus currently includes six species: Zaire ebolavirus (EBOV), Sudan ebolavirus, Reston ebolavirus, Taï Forest ebolavirus, Bundibugyo ebolavirus, and the newly identified Bombali ebolavirus [4,5,6]. EBOV was responsible for the 2014–2016 outbreak in West Africa and is responsible for the current outbreak in the DRC [7,8]. RVSV-ZEBOV, a replication-competent recombinant vesicular stomatitis virus (VSV)-based vector expressing the Vaccines 2020, 8, 215; doi:10.3390/vaccines8020215 www.mdpi.com/journal/vaccines
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
